Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Gamida Cell Ltd. (GMDA) presented updated data on its investigational therapy, omidubicel, at the 2022 TCT Meeting. This advanced stem cell therapy showed promising results in immune cell recovery and reduced infection rates compared to standard umbilical cord blood transplantation. The therapy's Biologics License Application (BLA) is on track for completion by Q2 2022. The presentation was awarded the TCT Best Abstract Award, reinforcing omidubicel's potential to transform blood cancer treatment.
- Omidubicel shows enhanced recovery of immune cells, potentially leading to lower infection rates.
- BLA submission for omidubicel is on track for completion in Q2 2022.
- Presentation received the TCT Best Abstract Award, highlighting the significance of the findings.
- None.
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant
- Oral presentation includes updated analysis demonstrating enhanced circulatory pDC, NK cell and CD4+ T cell recovery with omidubicel
- Rapid immune cell recovery results in reduced rates of infection; no increase in GvHD rates compared with standard umbilical cord transplantation
- Omidubicel BLA submission is on track to be completed in the second quarter of 2022
The presentation, which received a TCT Best Abstract Award, titled “Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel is Associated with Enhanced Circulatory Plasmacytoid Dendritic Cells (pDC), NK Cells and CD4+ T Cells with
“These data provide mechanistic support for the reduced infection rates seen with omidubicel-treated patients in the Phase 3 study, and clear demonstration of the benefits of omidubicel over standard cord blood transplantation, which can be associated with immune and hematopoietic recovery challenges that are devastating to patients,” said
In total,
About Omidubicel
Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies (blood cancers), for which it has been granted Breakthrough Status and orphan drug designation by the FDA. Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). For more information on clinical trials of omidubicel, please visit the
Omidubicel is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.
About NAM Technology
Our NAM-enabling technology is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM (nicotinamide), we are able to enhance, expand and metabolically modulate multiple cell types — including stem cells and natural killer cells — with appropriate growth factors to maintain the cells’ active phenotype and enhance potency. This allows us to administer a therapeutic dose of cells that may help cancer patients live longer better lives.
About
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including GDA-201), anticipated regulatory filings and the potentially life-saving or curative therapeutic and commercial potential of omidubicel. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 10-K, filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005350/en/
For investors:
Stern Investor Relations, Inc.
courtney.turiano@sternir.com
1-212-362-1200
For media:
Ten
rhiannon@tenbridgecommunications.com
1-978-417-1946
Source: